Form 4: Director Sumant Ramachandra Receives Lyell Option Grant

Lyell Immunopharma director Sumant Ramachandra was granted 9,250 stock options as part of standard director compensation.

Summary

• Director Sumant Ramachandra acquired 9,250 stock options in Lyell Immunopharma, Inc. (LYEL).
• The options have an exercise price of $13.22 per share.
• The grant is subject to a vesting schedule tied to the next annual stockholder meeting or the first anniversary of the grant date.
• The reporting person also maintains indirect ownership of 10,000 shares of common stock through a family trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine compensatory filing.

Risks

• The value of the granted options is dependent on the future market performance of LYEL common stock.

Future Outlook

The options vest on the earlier of the next annual stockholder meeting following June 10, 2026, or the first anniversary of the grant date, contingent on continuous service.

Industry Context

StockSavvy.ai notes that equity grants for directors are standard practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term clinical and commercial development.

Comparison to Industry Standards

• The grant structure is consistent with standard non-employee director compensation packages for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common governance practices to ensure board continuity.

Related Party Transactions

• The reporting person is the grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12, which holds 10,000 shares of common stock.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensatory equity grant.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Form 4, Insider Trading, Stock Options, Director Compensation